-
Nirmatrelvir
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Nirmatrelvir 2628280-40-8 [Indication]
Paxlovid is a co-packaged combination of nirmatrelvir, a second generation protease inhibitor, and ritonavir, a pharmacological enhancer for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older with body weight ≥40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
-
Niraparib Tosylate Monohydrate
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Niraparib Tosylate Monohydrate 1613220-15-7 ✓ Jan.8, 2028 Commercial Production [Indication]
1. Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
2. Maintenance treatment of adult patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.